{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T02:10:28Z","timestamp":1792548628762,"version":"4.5.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Med Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Tacrolimus (FK506) is an immunosuppressive agent and has toxic side effects such as nephrotoxicity, hepatotoxicity, and neurotoxicity. In our study, we aimed to investigate the protective effect of silymarin on renal and hepatic toxicity considered to be tacrolimus related.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this 6-week experimental study, 46 eight-week-old healthy male rats were used. The groups comprised the Control (healthy rats, n\u2009=\u20096), Tac (tacrolimus 1\u00a0mg\/kg, n\u2009=\u20098), silymarin 100\u00a0mg\/kg (SLI 100\u00a0mg\/kg n\u2009=\u20098), Tac\u2009+\u2009SLI 100 (tacrolimus 1\u00a0mg\/kg\u2009+\u2009SLI 100 n\u2009=\u20098), SLI 200 (SLI 200\u00a0mg\/kg n\u2009=\u20098), and Tac\u2009+\u2009SLI 200 (tacrolimus 1\u00a0mg\/kg\u2009+\u2009SLI 200\u00a0mg\/kg n\u2009=\u20098). After 6 weeks, all rats were sacrificed, and the tissue follow-up procedure was performed for kidney and liver tissues, histopathology, and in situ TUNEL analysis. Blood samples were analyzed for the total antioxidant capacity (TAC), total oxidant capacity (TOC), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), albumin, total bilirubin, creatine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Histopathological findings of kidney and liver tissue of rats were determined to increase statistically in Tac group compared to SLI 1 00 and SLI 200 groups (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). In addition, the Tac\u2009+\u2009SLI 100 and Tac\u2009+\u2009SLI 200 groups were found to be statistically similar to the Control group (<jats:italic>P<\/jats:italic>\u2009&gt;\u20090.05). The in situ TUNEL method showed that the tacrolimus increased apoptosis while the silymarin decreased it. TOC levels increased statistically in Tac groups compared to silymarin-treated groups (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). Although the TAC level was not statistically significant among the experimental groups (<jats:italic>P<\/jats:italic>\u2009&gt;\u20090.05), the lowest was measured in the Tac group. The ALT, AST, GGT, total bilirubin, and creatine values were higher in the Tac group than in the silymarin groups (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). There was no statistically significant difference between the groups with regard to the albumin level (<jats:italic>P<\/jats:italic>\u2009&gt;\u20090.05).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In our study, we determined that tacrolimus caused damage to kidney and liver tissue. Histopathological, biochemical and apoptotic findings show that silymarin has a protective effect against nephrotoxicity and hepatotoxicity caused by tacrolimus.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12906-022-03803-x","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T05:03:46Z","timestamp":1670907826000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Protective effect of silymarin on tacrolimus-induced kidney and liver toxicity"],"prefix":"10.1186","volume":"22","author":[{"given":"Funda","family":"Terzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa Kemal","family":"Ciftci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,13]]},"reference":[{"issue":"1","key":"3803_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0009-9120(00)00175-2","volume":"34","author":"VW Armstrong","year":"2001","unstructured":"Armstrong VW, Oellerich M. New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine. Clin Biochem. 2001;34(1):9\u201316.","journal-title":"Clin Biochem"},{"issue":"2","key":"3803_CR2","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s13105-015-0451-7","volume":"72","author":"H Ferjani","year":"2016","unstructured":"Ferjani H, El Arem A, Bouraoui A, Achour A, Abid S, Bacha H, Boussema-Ayed I. Protective effect of mycophenolate mofetil against nephrotoxicity and hepatotoxicity induced by tacrolimus in Wistar rats. J Physiol Biochem. 2016;72(2):133\u201344.","journal-title":"J Physiol Biochem"},{"issue":"12 Suppl","key":"3803_CR3","first-page":"S5","volume":"69","author":"JM Campistol","year":"2000","unstructured":"Campistol JM, Sacks SH. Mechanisms of nephrotoxicity. Transplantation. 2000;69(12 Suppl):S5\u201310.","journal-title":"Transplantation"},{"issue":"1","key":"3803_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.5507\/bp.2005.002","volume":"149","author":"V K\u0159en","year":"2005","unstructured":"K\u0159en V, Walterova D. Silybin and silymarin-new effects and applications. Biomedical Papers. 2005;149(1):29\u201341.","journal-title":"Biomedical Papers"},{"issue":"2","key":"3803_CR5","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2215\/CJN.04800908","volume":"4","author":"M Naesens","year":"2009","unstructured":"Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009;4(2):481\u2013508.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2 Suppl","key":"3803_CR6","doi-asserted-by":"publisher","first-page":"229S","DOI":"10.1016\/j.transproceed.2004.01.021","volume":"36","author":"A Busauschina","year":"2004","unstructured":"Busauschina A, Schnuelle P, van der Woude FJ. Cyclosporine nephrotoxicity. Transplant Proc. 2004;36(2 Suppl):229S-233S.","journal-title":"Transplant Proc."},{"issue":"1","key":"3803_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00011-004-1318-5","volume":"54","author":"S Miyata","year":"2005","unstructured":"Miyata S, Ohkubo Y, Mutoh S. A review of the action of tacrolimus (FK506) on experimental models of rheumatoid arthritis. Inflamm Res. 2005;54(1):1\u20139.","journal-title":"Inflamm Res"},{"issue":"5","key":"3803_CR8","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/0165-6147(93)90206-Y","volume":"14","author":"JFK Liu","year":"1993","unstructured":"Liu JFK. 506 and ciclosporin: molecular probes for studying intracellular signal transduction. Trends Pharmacol Sci. 1993;14(5):182\u20138.","journal-title":"Trends Pharmacol Sci"},{"issue":"2","key":"3803_CR9","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.transproceed.2004.01.021","volume":"36","author":"A Busauschina","year":"2004","unstructured":"Busauschina A, Schnuelle P, van der Woude FJ. \u00a0Cyclosporine nephrotoxicity. Transpl Proc. 2004;36(2):229\u201333.","journal-title":"Transpl Proc."},{"issue":"3","key":"3803_CR10","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1177\/152692480901900315","volume":"19","author":"M Vicari-Christensen","year":"2009","unstructured":"Vicari-Christensen M, Repper S, Basile S, Young D. Tacrolimus: review of pharmacokinetics, pharmacodynamics, and pharmacogenetics to facilitate practitioners\u2019 understanding and offer strategies for educating patients and promoting adherence. Prog Transpl. 2009;19(3):277\u201384.","journal-title":"Prog Transpl"},{"issue":"12","key":"3803_CR11","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.2165\/00003495-200363120-00006","volume":"63","author":"LJ Scott","year":"2003","unstructured":"Scott LJ, McKeage K, Keam SJ, Plosker GL. Tacrolimus. Drugs. 2003;63(12):1247\u201397.","journal-title":"Drugs"},{"key":"3803_CR12","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jss.2019.12.010","volume":"249","author":"A Nash","year":"2020","unstructured":"Nash A, Samoylova M, Leuthner T, Zhu M, Lin L, Meyer JN. Brennan TV.Effects of immunosuppressive medications on mitochondrial function. J Surg Res. 2020;249:50\u20137.","journal-title":"J Surg Res"},{"issue":"3","key":"3803_CR13","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1093\/ecam\/neh103","volume":"2","author":"G Karimi","year":"2005","unstructured":"Karimi G, Ramezani M, Tahoonian Z. Cisplatin nephrotoxicity and protection by milk thistle extract in rats. Evid -based Complement Altern Med. 2005;2(3):383\u20136.","journal-title":"Evid -based Complement Altern Med"},{"issue":"4","key":"3803_CR14","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2165\/00007256-200636040-00004","volume":"36","author":"J Finaud","year":"2006","unstructured":"Finaud J, Lac G, Filaire E. Oxidative stress. Sports Med. 2006;36(4):327\u201358.","journal-title":"Sports Med"},{"issue":"7","key":"3803_CR15","first-page":"271","volume":"45","author":"T Yoshikawa","year":"2002","unstructured":"Yoshikawa T, Naito Y. What is oxidative stress? Jpn Med Assoc J. 2002;45(7):271\u20136.","journal-title":"Jpn Med Assoc J."},{"key":"3803_CR16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.toxlet.2021.01.020","volume":"341","author":"R Fu","year":"2021","unstructured":"Fu R, Tajima S, Shigematsu T, Zhang M, Tsuchimoto A, Egashira N, Ieiri I, Masuda S. Establishment of an experimental rat model of tacrolimus-induced kidney injury accompanied by interstitial fibrosis. Toxicol Lett. 2021;341:43\u201350.","journal-title":"Toxicol Lett"},{"issue":"4","key":"3803_CR17","doi-asserted-by":"publisher","first-page":"219","DOI":"10.2131\/jts.19.4_219","volume":"19","author":"T Mitamura","year":"1994","unstructured":"Mitamura T, Yamada A, Ishida H, Fujihira S, Ohara K, Noguchi H, Mine Y. Tacrolimus (FK506)-induced nephrotoxicity in spontaneous hypertensive rats. J Toxicol Sci. 1994;19(4):219\u201326.","journal-title":"J Toxicol Sci"},{"key":"3803_CR18","doi-asserted-by":"crossref","unstructured":"Klein IHHT, Abrahams A, van Ede T, Hen\u00e9 RJ, Koomans HA, Ligtenberg G. Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. Transplantation. 2002;73(5):732-6.","DOI":"10.1097\/00007890-200203150-00012"},{"key":"3803_CR19","doi-asserted-by":"crossref","unstructured":"Nankivell BJ, Chapman JR, Bonovas G, Gruenewald SM.Oral cyclosporine but not tacrolimus reduces renal transplant blood flow. Transplantation. 2004;77(9):1457-459.","DOI":"10.1097\/01.TP.0000121196.71904.E0"},{"key":"3803_CR20","doi-asserted-by":"crossref","unstructured":"Kihm LP, Blume C, Seckinger J, Hankel V, Stoffler D, Morath C, Zeier M, Schwenger V. Acute effects of calcineurin inhibitors on kidney allograft microperfusion visualized by contrast-enhanced sonography. Transplantation. 2012;93(11):1125-9.","DOI":"10.1097\/TP.0b013e31824f3dae"},{"issue":"1","key":"3803_CR21","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1600-6143.2006.01576.x","volume":"7","author":"J O\u2019grady","year":"2007","unstructured":"O\u2019grady J, Hardy P, Burroughs A, Elbourne D, Group UK. Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: poststudy surveillance to 3 years. Am J Transplant. 2007;7(1):137\u201341.","journal-title":"Am J Transplant"},{"issue":"9340","key":"3803_CR22","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0140-6736(02)11196-2","volume":"360","author":"JG O\u2019Grady","year":"2002","unstructured":"O\u2019Grady JG, Burroughs A, Hardy P, Elbourne D, Truesdale A. Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial. Lancet. 2002;360(9340):1119\u201325.","journal-title":"Lancet"},{"issue":"1","key":"3803_CR23","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/00007890-199807150-00013","volume":"66","author":"S Sanchez-Campos","year":"1998","unstructured":"Sanchez-Campos S, Lopez-Acebo R, Gonzalez P, Culebras JM, Tunon MJ, Gonzalez-Gallego J. Cholestasis and alterations of glutathione metabolism induced by tacrolimus (FK506) in the rat. Transplantation. 1998;66(1):84\u20138.","journal-title":"Transplantation"},{"issue":"3","key":"3803_CR24","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1272\/jnms.75.187","volume":"75","author":"N Taniai","year":"2008","unstructured":"Taniai N, Akimaru K, Ishikawa Y, Kanada T, Kakinuma D, Mizuguchi Y, Mamada Y, Yoshida H. Tajiri T.Hepatotoxicity caused by both tacrolimus and cyclosporine after living donor liver transplantation. J Nippon Med School. 2008;75(3):187\u201391.","journal-title":"J Nippon Med School"},{"issue":"5","key":"3803_CR25","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3109\/0886022X.2013.780621","volume":"35","author":"DK Yadav","year":"2013","unstructured":"Yadav DK, Gera DN, Gumber MR, Kute VB, Patel MP, Vanikar AV. Trivedi HL.Tacrolimus-induced severe cholestasis complicating renal transplantation. Ren Fail. 2013;35(5):735\u20137.","journal-title":"Ren Fail"},{"issue":"1","key":"3803_CR26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1442-9071.2005.00942.x","volume":"33","author":"Y Akar","year":"2005","unstructured":"Akar Y, Yucel G, Durukan A, Yucel I, Arici G. Systemic toxicity of tacrolimus given by various routes and the response to dose reduction. Clin Exp Ophthalmol. 2005;33(1):53\u20139.","journal-title":"Clin Exp Ophthalmol"},{"issue":"10","key":"3803_CR27","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0955-2863(02)00208-5","volume":"13","author":"KE Heim","year":"2002","unstructured":"Heim KE, Tagliaferro AR, Bobilya DJ. Flavonoid antioxidants: chemistry, metabolism and structure-activity relationships. J Nutr Biochem. 2002;13(10):572\u201384.","journal-title":"J Nutr Biochem"},{"issue":"10","key":"3803_CR28","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1002\/ptr.3207","volume":"24","author":"AL Abenavoli","year":"2010","unstructured":"Abenavoli AL, Capasso R, Milic N, Capasso F. Milk thistle in liver diseases: past, present, future. Phytother Res. 2010;24(10):1423\u201332.","journal-title":"Phytother Res"},{"issue":"1","key":"3803_CR29","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0021-9673(02)01971-4","volume":"990","author":"F Kvasni\u010dka","year":"2003","unstructured":"Kvasni\u010dka F, B\u00edba B, \u0160ev\u010d\u00edk R, Vold\u0159ich M. Kr\u00e1tk\u00e1 J.Analysis of the active components of silymarin. J Chromatogr A. 2003;990(1):239\u201345.","journal-title":"J Chromatogr A"},{"issue":"1","key":"3803_CR30","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3390\/antiox4010204","volume":"4","author":"PF Surai","year":"2015","unstructured":"Surai PF. Silymarin as a natural antioxidant: an overview of the current evidence and perspectives. Antioxidants. 2015;4(1):204\u201347.","journal-title":"Antioxidants"},{"issue":"3","key":"3803_CR31","doi-asserted-by":"publisher","first-page":"144","DOI":"10.4254\/wjh.v6.i3.144","volume":"6","author":"N Vargas-Mendoza","year":"2014","unstructured":"Vargas-Mendoza N, Madrigal-Santill\u00e1n E, Morales-Gonz\u00e1lez \u00c1, Esquivel-Soto J, Esquivel-Chirino C, y Gonz\u00e1lez-Rubio MG-L, Gayosso-de-Lucio JA, Morales-Gonz\u00e1lez JA. Hepatoprotective effect of silymarin. World J Hepatol. 2014;6(3):144.","journal-title":"World J Hepatol"},{"issue":"3","key":"3803_CR32","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2174\/092986707779941159","volume":"14","author":"R Gazak","year":"2007","unstructured":"Gazak R, Walterova D, Kren V. Silybin and silymarin-new and emerging applications in medicine. Curr Med Chem. 2007;14(3):315\u201338.","journal-title":"Curr Med Chem"},{"issue":"4","key":"3803_CR33","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/hep.510230415","volume":"23","author":"C Dehmlow","year":"1996","unstructured":"Dehmlow C, Erhard J, de Groot H. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology. 1996;23(4):749\u201354.","journal-title":"Hepatology"},{"issue":"2","key":"3803_CR34","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1006\/phrs.1999.0575","volume":"41","author":"H Farghali","year":"2000","unstructured":"Farghali H, Kamenikova L, Hynie S, Kmonickova E. Silymarin effects on intracellular calcuim and cytotoxicity: a study in perfused rat hepatocytes after oxidative stress injury. Pharmacol Res. 2000;41(2):231\u20137.","journal-title":"Pharmacol Res"},{"issue":"2","key":"3803_CR35","first-page":"182","volume":"7","author":"Subir Kumar Das SMaDV","year":"2008","unstructured":"Subir Kumar Das SMaDV. Medicinal properties of milk thistle with special reference to silymarin an overview. Nat Prod Radiance. 2008;7(2):182\u201392.","journal-title":"Nat Prod Radiance"},{"issue":"1","key":"3803_CR36","first-page":"022","volume":"1","author":"L Radko","year":"2007","unstructured":"Radko L, Cybulski W. Application of silymarin in human and animal medicine. J Pre-Clinical Clin Res. 2007;1(1):022\u20136.","journal-title":"J Pre-Clinical Clin Res"},{"key":"3803_CR37","doi-asserted-by":"publisher","first-page":"119639","DOI":"10.1016\/j.ijpharm.2020.119639","volume":"587","author":"MHA Aboshanab","year":"2020","unstructured":"Aboshanab MHA, El-Nabarawi MA, Teaima MH, El-Nekeety AA, Abdel-Aziem SH, Hassan NS, Abdel-Wahhab MA. Fabrication, characterization and biological evaluation of silymarin nanoparticles against carbon tetrachloride-induced oxidative stress and genotoxicity in rats. Int J Pharm. 2020;587:119639.","journal-title":"Int J Pharm"},{"issue":"2","key":"3803_CR38","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1080\/13813455.2019.1620785","volume":"127","author":"E Heidarian","year":"2021","unstructured":"Heidarian E, Nouri A. Hepatoprotective effects of silymarin against diclofenac-induced liver toxicity in male rats based on biochemical parameters and histological study. Arch Physiol Biochem. 2021;127(2):112\u20138.","journal-title":"Arch Physiol Biochem"},{"key":"3803_CR39","doi-asserted-by":"publisher","first-page":"143966","DOI":"10.1016\/j.gene.2019.143966","volume":"712","author":"MM Ahmad","year":"2019","unstructured":"Ahmad MM, Rezk NA, Fawzy A, Sabry M. Protective effects of curcumin and silymarin against paracetamol induced hepatotoxicity in adult male albino rats. Gene. 2019;712:143966.","journal-title":"Gene"},{"issue":"3","key":"3803_CR40","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s11094-021-02405-0","volume":"55","author":"R Keshavarz-Maleki","year":"2021","unstructured":"Keshavarz-Maleki R, Shalmani AA, Gholami M, Sabzevari S, Rahimzadegan M, Jeivad F, Sabzevari O. The ameliorative effect of monomethyl fumarate and silymarin against valproic acid induced hepatotoxicity in rats. Pharm Chem J. 2021;55(3):240\u20135.","journal-title":"Pharm Chem J"},{"issue":"3","key":"3803_CR41","first-page":"1375","volume":"290","author":"J Sonnenbichler","year":"1999","unstructured":"Sonnenbichler J, Scalera F, Sonnenbichler I, Weyhenmeyer R. Stimulatory effects of silibinin and silicristin from the milk thistle Silybum marianum on kidney cells. J Pharmacol Exp Ther. 1999;290(3):1375\u201383.","journal-title":"J Pharmacol Exp Ther"},{"key":"3803_CR42","doi-asserted-by":"crossref","unstructured":"Nouri A, Heidarian E. Nephroprotective effect of silymarin against diclofenacinduced renal damage and oxidative stress in male rats. J Herbmed Pharmacol. 2019;8(2):146-52.","DOI":"10.15171\/jhp.2019.23"},{"issue":"6","key":"3803_CR43","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1080\/01480545.2019.1584208","volume":"43","author":"S Guzel","year":"2020","unstructured":"Guzel S, Sahinogullari ZU, Canacankatan N, Antmen SE, Kibar D, Coskun Yilmaz B. Potential renoprotective effects of silymarin against vancomycin-induced nephrotoxicity in rats. Drug Chem Toxicol. 2020;43(6):630\u20136.","journal-title":"Drug Chem Toxicol"},{"issue":"2","key":"3803_CR44","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1080\/01480545.2020.1733003","volume":"45","author":"B Dumludag","year":"2022","unstructured":"Dumludag B, Derici MK, Sutcuoglu O, Ogut B, Pasaoglu OT, Gonul II, Derici U. Role of silymarin (Silybum marianum) in the prevention of colistin-induced acute nephrotoxicity in rats. Drug Chem Toxicol. 2022;45(2):568\u201375.","journal-title":"Drug Chem Toxicol"},{"issue":"4","key":"3803_CR45","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.clinbiochem.2003.11.015","volume":"37","author":"O Erel","year":"2004","unstructured":"Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem. 2004;37(4):277\u201385.","journal-title":"Clin Biochem"},{"issue":"12","key":"3803_CR46","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.clinbiochem.2005.08.008","volume":"38","author":"O Erel","year":"2005","unstructured":"Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem. 2005;38(12):1103\u201311.","journal-title":"Clin Biochem"},{"issue":"5","key":"3803_CR47","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/j.transproceed.2008.12.035","volume":"41","author":"AB Karabulut","year":"2009","unstructured":"Karabulut AB, Ara C. Melatonin ameliorates tacrolimus (FK-506)\u2019s induced immunosupressive effect in rat liver. Transpl Proc. 2009;41(5):1875\u20137.","journal-title":"Transpl Proc."},{"issue":"2\u20133","key":"3803_CR48","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S0300-483X(97)00167-4","volume":"125","author":"KW Mollison","year":"1998","unstructured":"Mollison KW, Fey TA, Krause RA, Andrews JM, Bretheim PT, Cusick PK, Hsieh GC, Luly JR. Nephrotoxicity studies of the immunosuppressants tacrolimus (FK506) and ascomycin in rat models. Toxicology. 1998;125(2\u20133):169\u201381.","journal-title":"Toxicology"},{"issue":"2","key":"3803_CR49","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/01.TP.0000072337.37671.39","volume":"76","author":"L Butani","year":"2003","unstructured":"Butani L, Afshinnik A, Johnson J, Javaheri D, Peck S, German JB, Perez RV. Amelioration of tacrolimus-induced nephrotoxicity in rats using juniper oil. Transplantation. 2003;76(2):306\u201311.","journal-title":"Transplantation"},{"issue":"4","key":"3803_CR50","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1177\/1470320314530178","volume":"16","author":"NO Al-Harbi","year":"2015","unstructured":"Al-Harbi NO, Imam F, Al-Harbi MM, Iqbal M, Nadeem A, Al-Shahrah OA, Korashy HM, Al-Hosaini KA, Ahmed M, Bahashwar S. Treatment with aliskiren ameliorates tacrolimus-induced nephrotoxicity in rats. J Renin-Angiotensin-Aldosterone Syst. 2015;16(4):1329\u201336.","journal-title":"J Renin-Angiotensin-Aldosterone Syst"},{"key":"3803_CR51","doi-asserted-by":"crossref","unstructured":"Kedzierska K, Sporniak-Tutak K, Bober J, Safranow K, Olszewska M, Jakubowska K, Doma\u0144ski L, Go\u0142embiewska E, Kwiatkowska E, Laszczy\u0144ska M. Oxidative stress indices in rats under immunosuppression. In: Transplantation proceedings: 2011: Elsevier; 2011: 3939\u20133945.","DOI":"10.1016\/j.transproceed.2011.09.021"},{"issue":"1","key":"3803_CR52","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41401-020-0449-8","volume":"42","author":"H-L Zheng","year":"2021","unstructured":"Zheng H-L, Zhang H-Y, Zhu C-L, Li H-Y, Cui S, Jin J, Piao S-G, Jiang Y-J, Xuan M-Y, Jin J-Z. L-Carnitine protects against tacrolimus-induced renal injury by attenuating programmed cell death via PI3K\/AKT\/PTEN signaling. Acta Pharmacol Sin. 2021;42(1):77\u201387.","journal-title":"Acta Pharmacol Sin"},{"issue":"4","key":"3803_CR53","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/00125480-199707000-00032","volume":"4","author":"PS Randhawa","year":"1997","unstructured":"Randhawa PS, Starzl TE, Demetris AJ. Tacrolimus (FK506)-associated renal pathology. Adv Anat Pathol. 1997;4(4):265.","journal-title":"Adv Anat Pathol"},{"issue":"32","key":"3803_CR54","first-page":"2235","volume":"87","author":"Y Chen","year":"2007","unstructured":"Chen Y, Liang Y, Chen L, Liang J, Zhang J, Qiu J, Li W, Hu J, Xie K, Zhong W. Prevention of diltiazem in tacrolimus-induced nephrotoxicity: experiment with rats. Zhonghua Yi Xue Za Zhi. 2007;87(32):2235\u20137.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"9","key":"3803_CR55","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1007\/s00467-003-1196-z","volume":"18","author":"GE McLaughlin","year":"2003","unstructured":"McLaughlin GE, Schober M, Perez M, Ruiz P, Steele BW, Abitbol C. Benefit of theophylline administration in tacrolimus-induced nephrotoxicity in rats. Pediatr Nephrol. 2003;18(9):860\u20134.","journal-title":"Pediatr Nephrol"},{"issue":"7","key":"3803_CR56","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3923\/pjn.2010.624.636","volume":"9","author":"NE Abdelmeguid","year":"2010","unstructured":"Abdelmeguid NE, Chmaisse HN, Zeinab NSA. Protective effect of silymarin on cisplatin-induced nephrotoxicity in rats. Pak J Nutr. 2010;9(7):624\u201336.","journal-title":"Pak J Nutr"},{"issue":"7","key":"3803_CR57","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1016\/j.fct.2008.03.033","volume":"46","author":"NA El-Shitany","year":"2008","unstructured":"El-Shitany NA, El-Haggar S, El-Desoky K. Silymarin prevents adriamycin-induced cardiotoxicity and nephrotoxicity in rats. Food Chem Toxicol. 2008;46(7):2422\u20138.","journal-title":"Food Chem Toxicol"},{"key":"3803_CR58","unstructured":"Cengiz M. Renoprotective effects of Silybum marianum (L.) Gaertn (silymarin) on thioacetamide-induced renal injury: biochemical and histopathological approach. Pakistan J Pharmaceut Sci. 2018;31(5):2137-41."},{"key":"3803_CR59","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jobaz.2015.09.006","volume":"72","author":"AI Amien","year":"2015","unstructured":"Amien AI, Fahmy SR, Abd-Elgleel FM, Elaskalany SM. Renoprotective effect of Mangifera indica polysaccharides and silymarin against cyclophosphamide toxicity in rats. J Basic Appl Zool. 2015;72:154\u201362.","journal-title":"J Basic Appl Zool"},{"issue":"2","key":"3803_CR60","first-page":"367","volume":"36","author":"IA Mohammed","year":"2022","unstructured":"Mohammed IA, Shaban KA, Albadrany YM. Hepato-renal and hematological effects of flunixin and silymarin coadministration in rats. Iraqi J Vet Sci. 2022;36(2):367\u201373.","journal-title":"Iraqi J Vet Sci"},{"issue":"1","key":"3803_CR61","first-page":"25","volume":"22","author":"A Demetris","year":"1990","unstructured":"Demetris A, Fung J, Todo S, Banner B, Zerbe T, Sysyn G, Starzl T. Pathologic observations in human allograft recipients treated with FK 506. Transpl Proc. 1990;22(1):25\u201334.","journal-title":"Transpl Proc."},{"issue":"3","key":"3803_CR62","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1053\/hupa.2002.32225","volume":"33","author":"U Khettry","year":"2002","unstructured":"Khettry U, Backer A, Ayata G, Lewis WD, Jenkins RL. Gordon FD.Centrilobular histopathologic changes in liver transplant biopsies. Hum Pathol. 2002;33(3):270\u20136.","journal-title":"Hum Pathol"},{"issue":"4","key":"3803_CR63","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1080\/20014091084227","volume":"38","author":"J Whitfield","year":"2001","unstructured":"Whitfield J. Gamma glutamyl transferase. Crit Rev Clin Lab Sci. 2001;38(4):263\u2013355.","journal-title":"Crit Rev Clin Lab Sci."},{"issue":"8","key":"3803_CR64","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/S0891-5849(01)00471-3","volume":"30","author":"J Palomero","year":"2001","unstructured":"Palomero J, Gal\u00e1n AI, Mu\u00f1oz MaE, Tu\u00f1\u00f3n Ma J, Gonz\u00e1lez-Gallego J, Jim\u00e9nez R. Effects of aging on the susceptibility to the toxic effects of cyclosporin A in rats. Changes in liver glutathione and antioxidant enzymes. Free Radic Biol Med. 2001;30(8):836\u201345.","journal-title":"Free Radic Biol Med"},{"issue":"2","key":"3803_CR65","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1093\/ndt\/gfl608","volume":"22","author":"AK Khanna","year":"2006","unstructured":"Khanna AK, Pieper GM. NADPH oxidase subunits (NOX-1, p22phox, Rac-1) and tacrolimus-induced nephrotoxicity in a rat renal transplant model. Nephrol Dialysis Transpl. 2006;22(2):376\u201385.","journal-title":"Nephrol Dialysis Transpl"},{"key":"3803_CR66","first-page":"434","volume":"31","author":"A Ko\u00e7arslan","year":"2016","unstructured":"Ko\u00e7arslan A, Ko\u00e7arslan S, Aydin MS, Gunay \u015e, Karahan MA, Ta\u015fk\u0131n A, \u00dcstunel M, Aksoy N. Intraperitoneal administration of silymarin protects end organs from multivisceral ischemia\/reperfusion injury in a rat model. Brazilian J Cardiovasc Surg. 2016;31:434\u20139.","journal-title":"Brazilian J Cardiovasc Surg"},{"issue":"2","key":"3803_CR67","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s11255-008-9365-4","volume":"40","author":"F Turgut","year":"2008","unstructured":"Turgut F, Bayrak O, Catal F, Bayrak R, Atmaca AF, Koc A, Akbas A, Akcay A, Unal D. Antioxidant and protective effects of silymarin on ischemia and reperfusion injury in the kidney tissues of rats. Int Urol Nephrol. 2008;40(2):453\u201360.","journal-title":"Int Urol Nephrol"},{"issue":"1","key":"3803_CR68","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1159\/000449289","volume":"135","author":"HS Kim","year":"2017","unstructured":"Kim HS, Lim SW, Jin L, Jin J, Chung BH, Yang CW. The protective effect of febuxostat on chronic tacrolimus-induced nephrotoxicity in rats. Nephron. 2017;135(1):61\u201371.","journal-title":"Nephron"},{"key":"3803_CR69","doi-asserted-by":"crossref","unstructured":"Choi S, You H, Chung S: Tacrolimus-induced apoptotic signal transduction pathway. In: Transplantation proceedings: 2008: Elsevier; 2008: 2734\u20132736.","DOI":"10.1016\/j.transproceed.2008.08.028"},{"issue":"23","key":"3803_CR70","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1016\/S0024-3205(00)00554-3","volume":"66","author":"S Kochi","year":"2000","unstructured":"Kochi S, Takanaga H, Matsuo H, Ohtani H, Naito M, Tsuruo T, Sawada Y. Induction of apoptosis in mouse brain capillary endothelial cells by cyclosporin A and tacrolimus. Life Sci. 2000;66(23):2255\u201360.","journal-title":"Life Sci"},{"issue":"4","key":"3803_CR71","doi-asserted-by":"publisher","first-page":"734","DOI":"10.3109\/0886022X.2015.1012984","volume":"37","author":"DO Dabak","year":"2015","unstructured":"Dabak DO, Kocaman N. Effects of silymarin on methotrexate-induced nephrotoxicity in rats. Ren Fail. 2015;37(4):734\u20139.","journal-title":"Ren Fail"},{"issue":"1","key":"3803_CR72","doi-asserted-by":"publisher","first-page":"51","DOI":"10.4142\/jvs.2014.15.1.51","volume":"15","author":"M Sozmen","year":"2014","unstructured":"Sozmen M, Devrim AK, Tunca R, Bayezit M, Dag S, Essiz D. Protective effects of silymarin on fumonisin B1-induced hepatotoxicity in mice. J Vet Sci. 2014;15(1):51\u201360.","journal-title":"J Vet Sci"},{"issue":"3","key":"3803_CR73","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.tiv.2007.11.020","volume":"22","author":"J Doehmer","year":"2008","unstructured":"Doehmer J, Tewes B, Klein K-U, Gritzko K, Muschick H. Mengs U.Assessment of drug\u2013drug interaction for silymarin. Toxicol In Vitro. 2008;22(3):610\u20137.","journal-title":"Toxicol In Vitro"},{"issue":"9","key":"3803_CR74","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1124\/dmd.113.052563","volume":"41","author":"SJ Brantley","year":"2013","unstructured":"Brantley SJ, Graf TN, Oberlies NH, Paine MF. A systematic approach to evaluate herb-drug interaction mechanisms: investigation of milk thistle extracts and eight isolated constituents as CYP3A inhibitors. Drug Metab Dispos. 2013;41(9):1662\u201370.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"3803_CR75","first-page":"79","volume":"30","author":"C-S Kim","year":"2010","unstructured":"Kim C-S, Choi S-J, Park C-Y, Li C, Choi J-S. .Effects of silybinin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen in rats. Anticancer Res. 2010;30(1):79\u201385.","journal-title":"Anticancer Res"},{"issue":"6","key":"3803_CR76","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1124\/dmd.32.6.587","volume":"32","author":"C Sridar","year":"2004","unstructured":"Sridar C, Goosen TC, Kent UM, Williams JA, Hollenberg PF. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab Dispos. 2004;32(6):587\u201394.","journal-title":"Drug Metab Dispos"},{"issue":"15","key":"3803_CR77","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1080\/10826076.2011.629392","volume":"35","author":"Y Qi","year":"2012","unstructured":"Qi Y, Li G, Zhou Y, Wang M, Bi K, Dai R. Determination of FK506 in rat blood by LC-MS\/MS and effect of silymarin on its pharmacokinetics. J Liq Chromatogr Relat Technol. 2012;35(15):2217\u201327.","journal-title":"J Liq Chromatogr Relat Technol"},{"key":"3803_CR78","doi-asserted-by":"crossref","unstructured":"Gaston RS, Cecka JM, Kasiske BL, Fieberg AM, Leduc R, Cosio FC, Gourishankar S, Grande J, Halloran P, Hunsicker L, et al. Evidence for antibody-mediated Injury as a major determinant of late kidney allograft failure. Transplantation. 2010;90(1):68-74.","DOI":"10.1097\/TP.0b013e3181e065de"}],"container-title":["BMC Complementary Medicine and Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-022-03803-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12906-022-03803-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-022-03803-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T06:02:50Z","timestamp":1670911370000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccomplementalternmed.biomedcentral.com\/articles\/10.1186\/s12906-022-03803-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,13]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3803"],"URL":"https:\/\/doi.org\/10.1186\/s12906-022-03803-x","relation":{},"ISSN":["2662-7671"],"issn-type":[{"value":"2662-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,13]]},"assertion":[{"value":"17 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved by the Ethics Committee of Selcuk University (approval no:2015\/49). The animals were handled and used based on the international laboratory animals care and use guidelines. Furthermore, the study was conducted in agreement with the ARRIVE guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"331"}}